| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 278, Issue 35, 33456-33464, August 29, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Signal Transduction Laboratory, Institute of Molecular and Cell Biology, National University of Singapore, Singapore, 117609 Singapore
Received for publication, February 6, 2003 , and in revised form, June 4, 2003.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Mammalian Spry2 was recently shown to prolong EGF-stimulated MAPK signaling by attenuating EGFR ubiquitination and endocytosis (7, 8). Through its direct binding to the Ring finger domain of c-Cbl (9), which is an E3-ubiquitin ligase, hSpry2 appears to compete off the docking of c-Cbl onto the tyrosine-phosphorylated EGFR. Consequently, signals emanating from the EGFR are not attenuated but rather sustained. This study illustrated the dual function of Spry proteins in modulating the intensity and duration of MAPK signaling initiated by different RTKs.
Two interesting observations were made during the course of our previous study: (a) upon stimulation of RTKs, the association between c-Cbl and hSpry2 was significantly increased and (b) hSpry2 was highly tyrosine-phosphorylated. The question was asked whether Spry2 and c-Cbl exhibit another level of interaction following activation of RTKs, whether this centered around tyrosine phosphorylation of Spry2, and how this may impact on the modulatory effect of Spry2 on the Ras/MAPK pathway.
|
EXPERIMENTAL PROCEDURES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
Human c-Cbl cDNA was a kind gift from Dr. W. Langdon (University of Western Australia). The full-length c-Cbl cDNA and the various deletion mutants were constructed and subcloned into pXJ40HA vector as previously described (9). hSpry2 mutants were constructed using the site-directed mutagenesis kit from Clontech according to the manufacturer's instructions. The mutant products were derived using wild type FLAG-hSpry2 as template and verified by DNA sequencing.
Immunoprecipitation, Western Blotting, Cell Culture, and Confocal Microscopy—Immunoprecipitation, Western blotting and cell culture were performed as described previously (3). M2 (anti-FLAG-conjugated agarose) beads were used for immunoprecipitating FLAG-tagged proteins, whereas anti-HA-conjugated agarose beads were used for HA-tagged proteins. Confocal microscopy was carried out by seeding COS-7 cells onto 60-mm diameter tissue culture dishes in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. At 70% confluency, the cells were transfected with 1–2 µg of FLAG-tagged plasmid DNA using FuGENE 6 reagent (Roche Applied Science) according to the manufacturer's instructions. On the following day, the cells were trypsinized and plated into 6-well plates containing sterilized glass coverslips at a confluency of 30%. The cells were treated with or without EGF (50 ng/ml) for 30 min before fixing in 3% paraformaldehyde in PBSCM (phosphate-buffered saline containing 10 mM CaCl2 and 10 mM MgCl2) buffer for 30 min at room temperature, then permeabilized with 0.1% saponin (Sigma-Aldrich) in PBSCM for 15 min at room temperature. Anti-FLAG monoclonal antibody (Sigma-Aldrich) was used at 1 µg/100 µl in fluorescence dilution buffer (3% bovine serum albumin in PBSCM). After washing three times with PBSCM buffer, Texas Red dye-conjugated AffiniPure goat anti-mouse IgG (Jackson ImmunoResearch Laboratories Inc., West Groove, PA) was added to the cells at 1 µg/100 µl. The coverslips were mounted using Gel-Mount and viewed with an MRC-1024 (Bio-Rad) laser scanning confocal microscope.
Far Western Assay—FLAG-tagged hSpry constructs were transfected into HEK293T cells using FuGENE 6 reagent. 48 h after transfection, the cells were lysed, and the FLAG-tagged proteins were immunoprecipitated with M2 beads, followed by SDS-PAGE and transfer onto polyvinylidene difluoride membrane. The membrane was then blocked with 3% milk in PBST (phosphate-buffered saline containing 0.1% Tween 20) and then incubated with 1 µg/ml GST-c-Cbl protein diluted in 3% milk in PBST and 1 mM dithiothreitol for 2 h. Excess GST-c-Cbl protein was washed off thoroughly with PBST and probed with anti-GST monoclonal antibody (Santa Cruz Biotechnology), followed by anti-mouse horseradish peroxidase-conjugated secondary antibody (Sigma-Aldrich).
Receptor Down-regulation Assay—EGF receptor down-regulation assay was performed essentially as previously described (7)
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
|
The effects of FGFR activation on the hSpry2 tyrosine point mutations in HEK293T cells were next explored through the overexpression of FGFR1, which is constitutively active and hence mimics the sustained FGF signaling in developmental models. Similar to EGF stimulation, FGFR1 expression causes hSpry2 to be tyrosine-phosphorylated, as are the other point mutants with the exception of hSpry2Y55F (Fig. 1B). Endogenous c-Cbl was also demonstrated to be co-immunoprecipitated with hSpry2, as were the various tyrosine to phenylalanine mutants, again with the exception of hSpry2Y55F.
Substituting phenylalanine for tyrosine results in a change of charge at the target site. To investigate whether the charge change, rather than phosphorylation, was likely to be responsible for the loss of binding to c-Cbl, we further mutated Tyr55 to various other amino acids: alanine (neutral), proline (neutral), histidine (positively charged), and glutamic acid (negatively charged). These hSpry2 mutants were tested for binding to c-Cbl, and they all failed to bind (result not shown), indicating that the tyrosine residue is indeed necessary for c-Cbl interaction. These mutants also failed to be tyrosine-phosphorylated when stimulated with EGF or when co-expressed with FGFR1.
We next asked whether the tyrosine phosphorylation-induced interaction resulted in direct binding between c-Cbl and hSpry2. To this end we employed a far Western assay; a GST-c-Cbl fusion protein was generated and used to overlay a polyvinylidene difluoride blot of SDS-PAGE-resolved hSpry2 and hSpry2Y55F proteins overexpressed in HEK293T cells (Fig. 1C). The membrane was washed thoroughly to remove unbound GST-c-Cbl protein and subsequently probed with GST antibody. An intense band corresponding to the size of hSpry2 was observed in the immunoprecipitate of hSpry2 and FGFR1 co-expressing cells (Fig. 1C, second lane), whereas a weaker signal was observed in the immunoprecipitate from unstimulated, hSpry2-expressing cells (Fig. 1C, first lane). This clearly indicates that c-Cbl protein binds directly to hSpry2, both constitutively and with a significantly higher affinity for the tyrosine-phosphorylated hSpry2. The mutant hSpry2Y55F (Fig. 1C, third lane) also shows weak constitutive interaction with GST-c-Cbl with a slightly lower level of binding in the presence of FGFR1 co-expression (Fig. 1C, fourth lane). The immunoprecipitate from vector-expressing cells did not bind GST-c-Cbl (Fig. 1C, fifth and sixth lanes), hence indicating that the binding of c-Cbl to hSpry2 and hSpry2Y55F is specific.
We had previously characterized the constitutive binding of hSpry2 and c-Cbl (9). During these studies we observed that there appeared to be an enhanced interaction between these two proteins following RTK activation. We were interested in ascertaining the relative strength of binding between c-Cbl and hSpry2 pre- and post-stimulation of RTKs and to investigate the likely physiological outcome of this apparent dual mode of interaction. We consistently found that the interaction between c-Cbl and tyrosine-phosphorylated hSpry2 was significantly stronger than their constitutive binding. Both could be observed if sufficient protein was used in binding experiments. For clarity we tended to use lower amounts of lysates to "isolate" the phosphotyrosine-dependent binding. Therefore, constitutive interactions between c-Cbl and hSpry2 may not be always observed unless the experimental conditions are optimal.
Tyrosine 55 Embedded in a Conserved Motif on Spry2 Is Necessary for Enhanced c-Cbl Interaction—In view of the close homology of Spry2 residues 52–59 among all the Spry isoforms ((S/T)N(E/D)Y(T/V)(E/D)xP) (Fig. 2A), an alanine scan of these residues was performed to investigate their individual effect on c-Cbl binding. In the unstimulated state, these alanine mutants did not show any basal level of tyrosine phosphorylation, and c-Cbl was not detectable in the immunoprecipitates under the chosen experimental conditions (Fig. 2B). We then studied the ability of these mutants to interact with endogenous c-Cbl upon co-expression of FGFR1. Interestingly, singly mutating residues 53 and 59 to alanine also resulted in a loss of c-Cbl interaction, similar to the hSpry2Y55F mutant (Fig. 2C). Moreover, both 53A and 59A hSpry2 mutants were tyrosine-phosphorylated; notably, asparagine 53 and proline 59 (both with respect to hSpry2) are fully conserved among all Spry isoforms. The collective data indicate that hSpry2 phosphorylation, which evidence suggests occurs on tyrosine 55, can only enhance its binding with c-Cbl when the residues at the –2 (asparagine) and +4 (proline) positions relative to the tyrosine site (Tyr55) are both intact.
|
The SH2-like Domain of c-Cbl Binds to Tyrosine-phosphorylated hSpry2—c-Cbl possesses a sequence, the atypical SH2 domain, that has been characterized to bind directly to a tyrosine-phosphorylated motif. We next performed an experiment to verify this interaction employing constructs of c-Cbl that were used previously to characterize the constitutive interaction with hSpry2 (9). Fig. 3A shows the c-Cbl constructs with either C- or N-terminal deletions that were employed for subsequent interaction studies. FGFR1 was co-expressed with the various c-Cbl deletion mutants in the absence or presence of FLAG-hSpry2 in HEK293T cells. M2 beads were used for immunoprecipitation, followed by SDS-PAGE and Western blotting. The control experiment (Fig. 3B, left panel) indicates that the c-Cbl constructs do not interact nonspecifically with the M2 beads. In the presence of FLAG-hSpry2, c-Cbl constructs FL, NR, or NO were co-immunoprecipitated (Fig. 3B, right panel) but not constructs lacking the SH2-like domain (NS or CR). Because FLAG-hSpry2 protein in the current experiment was stimulated by FGFR1 overexpression and hence tyrosine-phosphorylated, compelling evidence (comparing the binding capabilities of NO and NS) indicates that the SH2-like domain of c-Cbl is responsible for binding to tyrosine-phosphorylated hSpry2.
|
As mentioned earlier there is a differential degree of binding between c-Cbl and hSpry2 in the unstimulated and stimulated conditions (Fig. 1C). The c-Cbl constructs containing the Ring finger motif were previously shown to bind GST-hSpry2 constitutively (9). To further illustrate the existence of this constitutive interaction in vivo, we repeated the experiment shown in Fig. 3B without FGFR1 co-expression. A set of c-Cbl constructs similar to those employed in Fig. 3A were used, with the addition of the c-Cbl construct CO (which does not have the Ring finger motif on the C-terminal; shown in Fig. 3C) as an appropriate control for CR. The result depicted in Fig. 3D demonstrates that c-Cbl constructs retaining the Ring finger motif (FL, NR, and CR) can be co-immunoprecipitated with hSpry2. A larger amount of cell lysate was employed in this experiment, which reinforces the notion that the constitutive interaction between c-Cbl and hSpry2 is relatively weak when compared with the phosphorylated tyrosine/SH2 interaction.
Spry2Y55F Mutant Fails to Retain EGFR at the Cell Surface—We had previously shown that hSpry2, via an interaction with c-Cbl, inhibited the internalization of EGFRs, which subsequently led to a sustained activation of the MAPK pathway (7). c-Cbl has been shown to bind phosphotyrosine 1045 on EGFR (10), which is contained within a sequence that shares close homology to the conserved Spry motif shown in Fig. 2A. A possible mechanism for the hSpry2-mediated inhibition of EGFR endocytosis is that Tyr55-phosphorylated hSpry2 offers an alternative binding site for the SH2-like domain of c-Cbl, which would compete for the binding of c-Cbl to tyrosine-phosphorylated EGFRs and therefore subsequently inhibit receptor ubiquitination. In essence it would be the SH2/Tyr55 phosphorylation motif interaction that would mediate the observed EGFR-inhibited endocytosis rather than the constitutive and weaker interaction between hSpry2 and the c-Cbl Ring finger domain. In this modified hypothesis hSpry2Y55F should be unable to inhibit c-Cbl-mediated EGFR endocytosis. To this end we compared the effects of wild type hSpry2 and hSpry2Y55F on the rate of EGFR internalization. COS-7 cells were again employed in this experiment because of the high level of endogenous EGFR. As depicted in Fig. 4A, whereas c-Cbl-transfected COS-7 cells enhanced the rate of internalization of activated EGFR, cells doubly transfected with c-Cbl and hSpry2 showed an impeded endocytosis, consistent with the reported role of hSpry2 (7, 8). Conversely, c-Cbl/hSpry2Y55F transfectants failed to block receptor endocytosis, and the surface EGFR levels were observed to decrease at basal rates. The equal expression level of the various constructs is shown in Fig. 4B.
|
A prominent role of c-Cbl in regulating RTK signaling is to function as an E3-ubiquitin ligase, acting on substrates such as the EGFR (10). We had previously shown that hSpry2 can interfere with c-Cbl ubiquitination of EGFR because of the competition for the Ring finger domain of c-Cbl with the E2-ubiquitin ligase, UbcH7 (7). Because our current data indicates that hSpry2Y55F protein does not exhibit an enhanced interaction with c-Cbl upon RTK stimulation, this construct is therefore useful to address whether the constitutive or tyrosine phosphorylation-dependent binding with c-Cbl is important to modulate EGFR ubiquitination. HA-ubiquitin together with c-Cbl, hSpry2, and hSpry2Y55F constructs were transfected into HEK293T cells, and the resultant SDS-PAGE-separated lysates were Western blotted and probed for the presence of ubiquitin-conjugated proteins in EGFR immunoprecipitates, as previously described (7). Wild type hSpry2 was observed to significantly block the conjugation of ubiquitin onto EGFR, whereas the Y55F mutant exhibited a reduced albeit significant ubiquitination of EGFR (Fig. 4C). This indicates that tyrosine phosphorylation of hSpry2 is a necessary step in the reduction of the c-Cbl-directed ubiquitination of EGFR and the subsequent attenuation in the endocytosis of activated receptors. The partial inhibition of EGFR ubiquitination by the Y55F mutant may be due to the previously characterized weak constitutive interaction via the N-terminal region of Spry2 with the Ring finger domain of c-Cbl (9).
The C termini of Spry proteins contain a cysteine-rich domain that is responsible for their translocation into membrane ruffles upon stimulation (11). The failure of Spry2 to translocate into the cell periphery is known to result in a loss of Spry2 function, including inhibition of cell proliferation and migration (12). It is possible hSpry2Y55F, because of a resultant alteration in tertiary structure, was simply unable to translocate, which would explain its inability to function like its wild type counterpart. We ascertained, by employing confocal microscopy, the ability of hSpry2Y55F to translocate into membrane ruffles. In unstimulated COS-7 cells, we observed that both wild type hSpry2 (Fig. 4D, panel a) and hSpry2Y55F (Fig. 4D, panel c) exhibited strong staining that corresponded to a microtubule location, as described previously (11). The addition of EGF (50 ng/ml) for 10 min induced the translocation of both hSpry2 (Fig. 4D, panel b) and hSpry2Y55F (Fig. 4D, panel d) to the cell periphery, notably membrane ruffles. It is therefore unlikely that hSpry2Y55F loses its ability to retain EGFR on the cell surface because of faulty targeting.
We had previously established a paradigm for Spry isoforms that an intact Spry translocation domain (residues 178–282) was necessary for function (11). Because the point mutation of hSpry2Y55F does not impact on this function, it has become apparent that the phosphorylation of hSpry2 (probably on the Tyr55 residue) and the presence of the asparagine (position –2) and proline (position +4) that flank Tyr55 are necessary for hSpry2 interaction with c-Cbl in the context of inhibiting EGFR endocytosis. This further indicates that both the highly conserved cysteine-rich domain as well as the equally highly conserved three residues centered on Tyr55 (hSpry2) are essential for Spry functions.
Tyrosine-phosphorylated hSpry2 Does Not Effect the Ubiquitination of
FGFR or FRS2—Because hSpry2 appears to divert a ubiquitination
process away from the EGFRs, we were interested to see whether there is any
hSpry2/c-Cbl redistribution of ubiquitination in the FGFR system. Recently,
c-Cbl was shown to partially attenuate FGFR signaling by both ubiquitination
of FGFR and its necessary docker protein FRS2
(13). Because these two
molecules are key components of the FGFR signaling pathway, regulation of
their activity or alteration of their cellular levels would be expected to
have a profound effect on the magnitude of the FGFR-mediated signal. We
therefore employed a similar protocol to that described for ubiquitination of
EGFR (Fig. 4C), and
the results of a typical experiment are shown in
Fig. 5. The conjugation of
ubiquitin molecules onto FGFR1 was clearly not affected by hSpry2 but was
partially affected by the Y55F mutant. In the case of FRS2, the basal
level of ubiquitination was also not elevated with co-expression of FGFR1
(Fig. 5B).
Overexpression of c-Cbl also did not result in enhanced ubiquitination,
suggesting that the predominant E3-ubiuquitin ligase for FRS2 may not
be c-Cbl. This could account for the inability of hSpry2, which binds avidly
to c-Cbl upon FGFR1 co-expression, to alter FGFR1 and FRS2
ubiquitination levels as it does for EGFR. This possibility was also eluded to
in a previous study (13).
|
Inhibition of FGFR-induced MAPK Inhibition by hSpry2 Depends on Its Stimulated Interaction with c-Cbl—Although Spry effects EGF pathways by binding c-Cbl, post-tyrosine phosphorylation, and effecting ubiquitination targets, it appears that the hSpry2/c-Cbl interaction in the context of the FGFR pathway may alternatively center around the ability of c-Cbl to act as a docking protein for other proteins and the likely redistribution of protein complexes following hSpry2 tyrosine phosphorylation. We therefore addressed whether tyrosine phosphorylation of hSpry2 per se or the binding of c-Cbl was essential to the ability of hSpry2 to inhibit the FGFR-stimulated Ras/MAPK pathway. To address this question we employed the various alanine mutants characterized in the early part of this study: hSpry2Y55A, which does not bind c-Cbl nor become tyrosine-phosphorylated, and hSpry2N53A and hSpry2P59A, both of which are tyrosine-phosphorylated but do not bind c-Cbl.
The basal activation/repression of ERK by the alanine mutants was initially assessed by probing SDS-PAGE separated and Western blotted lysates with a phospho-ERK antibody that detects the phosphorylation of p44/p42(ERK1/2) on threonine 202 and tyrosine 204 residues (Fig. 6A). FGFR1 was then co-expressed into these cells to elevate ERK activity. Interestingly, hSpry2 mutants that failed to bind c-Cbl in a stimulation-dependent manner displayed a parallel loss of ERK inhibitory function (Fig. 6, B and C). It therefore appears that the inhibition of the FGFR-stimulated MAPK pathway by hSpry2 likely also involves stimulated binding to c-Cbl and not solely on tyrosine phosphorylation of hSpry2 protein.
|
An additional ubiquitination experiment demonstrated that when the ubiquitin-incompetent c-Cbl(C381A) point mutant was transfected into 293T cells, hSpry2 was still able to attenuate the FGFR-induced MAPK pathway (results not shown). This indicates that the Spry-induced down-regulation, while seemingly needing the activated involvement of c-Cbl, does not require the inherent ubiquitin E3 transferase activity of this associating protein to fulfill its physiological role.
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
The main targets of our current experiments were: (a) to investigate possible tyrosine phosphorylation of Spry proteins, (b) to identify protein(s) that bind to hSpry2 and assist in the down-regulation of the Ras/MAPK in the context of FGF-stimulated signaling or attenuate EGFR down-regulation, and (c) to advance toward plausible mechanisms that explain both phenomena. In this regard we established that Tyr55 of hSpry is potentially tyrosine-phosphorylated following activation of several RTKs (EGFR and FGFR) and that this and two flanking amino acid residues (Asn53 and Pro59) located on a postulated effector loop are necessary to interact with a putative effector protein to fulfill the modulatory effects of hSpry2 on the Ras/MAPK pathway. Based on previous observations pertaining to the increased interaction of c-Cbl and hSpry following FGFR stimulation, we asked whether c-Cbl is a likely candidate for the effector protein. The strong correlative evidence presented suggests that c-Cbl may also play a role in hSpry2 inhibition of the Ras/MAPK pathway as well as the attenuation of EGFR down-regulation. Point mutations of the protein are most likely to disrupt only the most pertinent interactions. It is also noteworthy that point mutations at Asn53, Tyr55, and Pro59 on the hSpry2 protein individually disrupt post-FGFR-stimulated binding to c-Cbl, and each mutation correlates with an inability to inhibit the Ras/MAPK pathway. Previously Sasaki et al. (14) have also shown Spry2Y55A to be a dominant negative mutant that failed to inhibit FGF-induced ERK activation. Our current observation provides a cogent explanation as to why Spry2Y55A should function as a dominant negative mutant. From the assembled evidence two models can be proposed that may shed light on the mechanism of action for hSpry2 in respect to (a) the retention of EGFRs on the cell surface and (b) the inhibition of the FGFR-induced Ras/MAPK inhibition.
A summary of the "normal" activation/down-regulation of the EGFR in respect to the MAPK pathway can be described as follows. Binding of EGF induces receptor dimerization, which subsequently causes transphosphorylation of various tyrosine residues on the intracellular domain of EGFR. Two of these are described for illustrative purposes' Tyr1068 is a canonical target for the SH2 domain of Grb2 (YXN) and when phosphorylated results in the linked-activation of MAPK (15). At the same time another residue Tyr1045, when phosphorylated, is a well characterized binding motif for the SH2 domain of c-Cbl (10). The intimate association with c-Cbl allows for tagging of the EGFR with polyubiquitin, which further down the endocytic pathway becomes the recognition signal for protein destruction (10). The Ring finger domain of c-Cbl in this context fulfills its role as an E3-ubiquitin ligase, accepting ubiquitin moieties from an E2-ubiquitin-conjugating enzyme, which has been characterized as UbcH7 in the EGFR context. There is thus a balance between activation and attenuation involving the covalent modifications of phosphorylation and ubiquitination on the signal-instigating EGFR.
It has been shown that the hSpry2 gene is induced as a result of MAPK stimulation (16). In the activated context hSpry2 would target phosphatidylinositol 4,5-bisphosphate in the plasma membrane (17). Both hSpry2 and EGFR had been shown to be enriched in membrane ruffles (11). hSpry2 in this location also becomes tyrosine-phosphorylated, either directly or indirectly by the RTK, and the Tyr55 residue offers an alternative site for the SH2 domain of c-Cbl to bind to. It is predicted that "activated" hSpry2 therefore diverts the ubiquitin destruction tag away from the EGFR, which is subsequently retained on the surface of the cells, with the Ras/MAPK pathway in the "switched on" state (7, 8). hSpry2 itself is also a likely substrate of c-Cbl (see "Addendum").
The weaker constitutive binding between hSpry2 and c-Cbl may play a role in positioning the interacting partners in close proximity to each other prior to activation. There are a number of examples in the cellular context where low affinity binding precedes a more definitive and physiologically relevant high affinity interaction.
The proposed model for the interaction of hSpry2 with the FGFR system is
currently incomplete but demonstrates clear differences from the EGFR system.
The current best understanding of the upstream activation of the Ras/MAPK
pathway comes from a series of publications from the Schlessinger laboratory
(18,
19). There are four
phosphotyrosines on FRS2 possessing a canonical Grb2-SH2 binding motif
(18) and two downstream
phosphotyrosines possessing a canonical binding site for the SH2 domain of the
Shp2 tyrosine phosphatase
(19). According to current
concepts the majority of the MAPK activation pathway comes from the Shp2
connection, which then binds Grb2 and subsequently involves downstream
molecules similar to those of the EGFR pathway. It is proposed that where the
SH2 domain of Grb2 binds directly to FRS2, the SH3 domain binds to c-Cbl via a
SH3/proline-rich binding interaction
(13). c-Cbl competes with SOS
for the N-terminal SH3 domain of Grb2 and thus nullifies signaling to the
Ras/MAPK pathway. This represents another example of the balance of
"off" and "on" signals juxtaposed on the same
signaling molecule.
When hSpry2 appears on the scene in the FGFR context, what happens next is less clear. The targeting into a receptor proximal location will be similar to that with the EGFR system. Activated hSpry2 binds to c-Cbl and then may inhibit the activation of the Ras/MAPK pathway via any of a number of plausible mechanisms: (a) by sequestering c-Cbl away from FRS2, there may be some destabilization of the signaling balance eluded to above; or (b) c-Cbl, functioning as a docker protein (20), may sequester a key effector of the MAPK pathway or bring a regulator into a favorable location to fulfill its function. The evidence presented in this manuscript indicates that ubiquitination diversion is less likely to play a role in the FGFR signaling modification brought about by the strategic positioning of "activated" hSpry2, although FGFR, FRS2, and hSpry2 are all ubiquitinated. However, it appears that the interaction of hSpry and c-Cbl is still central to both proposed mechanisms.
Sequence alignment and analysis of all the Sprys from various species ranging from Drosophila to man indicates that two domains are stringently conserved. The first is the Spry translocation domain that includes the majority of the C-terminal cysteine-rich domain and includes a Arg252 residue (also 100% conserved) that has been shown to be essential for binding the phosphatidylinositol 4,5-bisphosphate (17). The second is the NXY*XXXP motif (where Y* represents a potential phosphotyrosine site) that is essential for Spry2 functionality. Currently the only known interacting protein with this sequence is c-Cbl. Various signaling proteins have been implicated as being involved in the function of Spry isoforms (21, 22). A direct effect on FRS2, for instance, would provide a feasible target with respect to FGFR signaling because it is strategically placed in originating and modifying the disposition of all downstream signaling. FRS2, however, is not found in Drosophila, and if a universal mechanism of hSpry2 function exists, the ubiquitous Cbl family may be more plausible as partners at the center of Spry function.
Addendum—While this manuscript was under review, Hanafusa et al. (23) reported the FGF-stimulated phosphorylation of Spry2 on the same tyrosine residue as described in this paper. At the same time, Rubin et al. (24) and Hall et al. (25) also reported that Spry2 is a target for c-Cbl-mediated ubiquitination and degradation.
|
FOOTNOTES |
|---|
To whom correspondence should be addressed: Signal Transduction Laboratory,
Institute of Molecular and Cell Biology, National University of Singapore, 30
Medical Dr., Singapore 117609, Singapore. Tel.: 65-68743737; Fax: 65-67791117;
E-mail:
mcbgg{at}imcb.nus.edu.sg.
1 The abbreviations used are: dSpry, Drosophila Sprouty; RTK,
receptor tyrosine kinase; MAPK, mitogen-activated protein kinase; FGF,
fibroblast growth factor; FGFR, FGF receptor; EGF, epidermal growth factor;
EGFR, EGF receptor; ERK, extracellular signal-regulated protein kinase; GST,
glutathione S-transferase; E2, ubiquitin carrier protein; E3,
ubiquitin-protein isopeptide ligase; HA, hemagglutinin.
|
ACKNOWLEDGMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONEXPERIMENTAL PROCEDURESRESULTSDISCUSSIONREFERENCES |
|---|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Edwin and T. B. Patel A Novel Role of Sprouty 2 in Regulating Cellular Apoptosis J. Biol. Chem., February 8, 2008; 283(6): 3181 - 3190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lito, B. D. Mets, S. Kleff, S. O'Reilly, V. M. Maher, and J. J. McCormick Evidence That Sprouty 2 Is Necessary for Sarcoma Formation by H-Ras Oncogene-transformed Human Fibroblasts J. Biol. Chem., January 25, 2008; 283(4): 2002 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chandramouli, C. Y. Yu, P. Yusoff, D.-H. Lao, H. F. Leong, K. Mizuno, and G. R. Guy Tesk1 Interacts with Spry2 to Abrogate Its Inhibition of ERK Phosphorylation Downstream of Receptor Tyrosine Kinase Signaling J. Biol. Chem., January 18, 2008; 283(3): 1679 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sutterluty, C.-E. Mayer, U. Setinek, J. Attems, S. Ovtcharov, M. Mikula, W. Mikulits, M. Micksche, and W. Berger Down-Regulation of Sprouty2 in Non-Small Cell Lung Cancer Contributes to Tumor Malignancy via Extracellular Signal-Regulated Kinase Pathway-Dependent and -Independent Mechanisms Mol. Cancer Res., May 1, 2007; 5(5): 509 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-H. Lao, P. Yusoff, S. Chandramouli, R. J. Philp, C. W. Fong, R. A. Jackson, T. Y. Saw, C. Y. Yu, and G. R. Guy Direct Binding of PP2A to Sprouty2 and Phosphorylation Changes Are a Prerequisite for ERK Inhibition Downstream of Fibroblast Growth Factor Receptor Stimulation J. Biol. Chem., March 23, 2007; 282(12): 9117 - 9126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bundschu, U. Walter, and K. Schuh The VASP-Spred-Sprouty Domain Puzzle J. Biol. Chem., December 1, 2006; 281(48): 36477 - 36481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-H. Lao, S. Chandramouli, P. Yusoff, C. W. Fong, T. Y. Saw, L. P. Tai, C. Y. Yu, H. F. Leong, and G. R. Guy A Src Homology 3-binding Sequence on the C Terminus of Sprouty2 Is Necessary for Inhibition of the Ras/ERK Pathway Downstream of Fibroblast Growth Factor Receptor Stimulation J. Biol. Chem., October 6, 2006; 281(40): 29993 - 30000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cabrita, F. Jaggi, S. P. Widjaja, and G. Christofori A Functional Interaction between Sprouty Proteins and Caveolin-1 J. Biol. Chem., September 29, 2006; 281(39): 29201 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Choi, S.-Y. Cho, R. H. Schwartz, and K. Choi Dual Effects of Sprouty1 on TCR Signaling Depending on the Differentiation State of the T Cell J. Immunol., May 15, 2006; 176(10): 6034 - 6045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. DaSilva, L. Xu, H. J. Kim, W. T. Miller, and D. Bar-Sagi Regulation of sprouty stability by mnk1-dependent phosphorylation. Mol. Cell. Biol., March 1, 2006; 26(5): 1898 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hu and S. R. Hubbard Structural Characterization of a Novel Cbl Phosphotyrosine Recognition Motif in the APS Family of Adapter Proteins J. Biol. Chem., May 13, 2005; 280(19): 18943 - 18949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Takayama, P. May, R. G. W. Anderson, and J. Herz Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Controls Endocytosis and c-CBL-mediated Ubiquitination of the Platelet-derived Growth Factor Receptor {beta} (PDGFR{beta}) J. Biol. Chem., May 6, 2005; 280(18): 18504 - 18510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Timpson, D. K. Lynch, D. Schramek, F. Walker, and R. J. Daly Cortactin Overexpression Inhibits Ligand-Induced Down-regulation of the Epidermal Growth Factor Receptor Cancer Res., April 15, 2005; 65(8): 3273 - 3280. [Abstract] [Full Text] [PDF] |
) or together with either 4 µg of
hSpry2 (•) or hSpry2Y55F (
) per 100-mm dish before subculture into a
24-well plate. At 48 h post-transfection, duplicate wells were incubated with
EGF (100 ng/ml) at 37 °C for various time intervals as indicated. Unbound
EGF was then washed off, and the levels of surface EGFR were determined by a
competitive binding assay with 125I-EGF (see "Experimental
Procedures"). Control cells were not exposed to EGF (
). The
average of duplicate determinations ± S.E. was expressed as the
percentage of total radioactivity at time 0. The experiment was repeated
twice. B, a Western blot analysis demonstrating the various protein
expression. IB, immunoblot. C, hSpry2Y55F fails to inhibit
c-Cbl ubiquitination of EGFR. 1 µg of HA-ubiquitin and 1 µg of
Myc-tagged EGFR cDNA were transfected into 60-mm dishes of HEK293T cells
together with hSpry2/Y55F constructs (1 µg) or c-Cbl (1 µg) or alone
(control). 48 h post-transfection, 3 µg of Myc antibody and protein A/G
beads were used to immunoprecipitate (IP) EGFR from the cell lysate.
The immunoprecipitates were resolved on 7.5% SDS-PAGE and immunoblotted
(IB) for ubiquitin using HA antibody. Expressions of the various
transfected plasmids were shown using the indicated antibodies. D,
hSpry2Y55F translocates to the cell membrane upon EGF stimulation. FLAG-tagged
hSpry2 and hSpry2Y55F were transfected into COS-7 cells and serum-starved for
16 h. EGF (50 ng/ml) was added to designated wells to stimulate the endogenous
EGFR for 10 min. Subsequently, the ligand was washed off with
phosphate-buffered saline, and the cells were fixed and stained for hSpry2
using FLAG antibody as stated under "Experimental Procedures."
